The levels of circulating markers of atherosclerosis and inflammation in subjects with different degrees of body mass index: Soluble CD40 ligand and high-sensitivity C-reactive protein

Thrombosis Research

Volumn 119, Issue 1, 2007, Pages 79-84

  Guldiken, Sibel ^a   Demir, Muzaffer ^a   Arikan, Ender ^a   Turgut, Burhan ^a   Azcan, Sennur ^a   Gerenli, Murat ^a   Tugrul, Armagan ^a  

^a NONE

Author keywords

Atherosclerosis; C reactive protein; Inflammation; Obesity; sCD40L

Indexed keywords

C REACTIVE PROTEIN; CD40 LIGAND; INSULIN;

ADULT; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR MALFORMATION; CONTROLLED STUDY; CORRELATIONAL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HOMEOSTASIS; HUMAN; INFLAMMATION; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN INTERACTION; RISK FACTOR; SENSITIVITY ANALYSIS; STATISTICAL SIGNIFICANCE;

ADULT; ANTIGENS, CD40; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BODY MASS INDEX; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CD40 LIGAND; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INFLAMMATION; MALE; OBESITY; RISK FACTORS;

EID: 33750840076     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2005.12.019     Document Type: Article

References (23)

1. Jonsson S., Hedblad B., Engstrom G., Nilsson P., Berglund G., and Janzon L. Influence of obesity on cardiovascular risk. Twenty-three-year follow up of 22,025 men from an urban Swedish population. Int J Obes Relat Metab Disord 26 (2002) 1046-1053
2. Kim K.S., Owen W.L., Williams D., and Adams-Campbell L.L. A comparison between BMI and Conicity index on predicting coronary heart disease: the Framingham Heart Study. Ann Epidemiol 10 (2000) 424-431
3. Yudkin J.S., Stehouwer C.D., Emeis J.J., and Coppack S.W. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?. Arterioscler Thromb Vasc Bio 19 (1999) 972-978
4. Piche M.E., Lemieux S., Weisnagel S.J., Corneau L., Nadeau A., and Bergeron J. Relation of high-sensitivity C-reactive protein, interleukin-6, tumor necrosis factor-alpha, and fibrinogen to abdominal adipose tissue, blood pressure, and cholesterol and triglyceride levels in healthy postmenopausal women. Am J Cardiol 96 (2005) 92-97
5. Schönbeck U., and Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci 58 (2001) 4-43
6. Schönbeck U., and Libby P. CD40 signaling and plaque instability. Circ Res 89 (2001) 1092-1103
7. Aukrust P., Muller F., Ueland T., Berget T., Aaser E., Brunsvig A., et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 100 (1999) 614-620
8. Cipollone F., Mezzetti A., Porreca E., Di Febbo C., Nutini M., Fazia M., et al. Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy. Circulation 106 (2002) 399-402
9. Schönbeck U., Varo N., Libby P., Buring J., and Ridker P.M. Soluble CD40L and cardiovascular risk in women. Circulation 104 (2001) 2266-2268
10. The expert committee on the diagnosis and classification of diabetes mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 26 (2003) S5-S20
11. World Health Organization. Obesity: Preventing and managing in global epidemic. Report of a WHO Consultation on Obesity. Geneva, June (1997)
12. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and β cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
13. Davi G., Guagnano M.T., Ciabattoni G., Basili S., Falco A., Marinopiccoli M., et al. Platelet activation in obese women: role of inflammation and oxidant stress. JAMA 288 (2002) 2008-2014
14. André P., Nannizzi-Alaimo L., Prasad S.K., and Phillips D.R. Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation 106 (2002) 896-899
15. Pignatelli P., Sanguigni V., Lenti L., Ferro D., Finocchi A., Rossi P., and Violi F. gp91phox-dependent expression of platelet CD40 ligand. Circulation 110 (2004) 1326-1329
16. Desideri G., and Ferri C. Effects of obesity and weight loss on soluble CD40L levels. JAMA 289 (2003) 1781-1782
17. Desideri G., Simone M., Iughetti L., Rosato T., Iezzi M.L., Marinucci M.C., et al. Early activation of vascular endothelial cells and platelets in obese children. J Clin Endocrinol Metab 90 (2005) 3145-3152
18. Furukawa S., Fujita T., Shimabukuro M., Iwaki M., Yamada Y., Nakajima Y., et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 114 (2004) 1752-1761
19. Hak A.E., Stehouwer C.D., Bots M.L., Polderman K.H., Schalkwijk C.G., Westendorp I.C., et al. Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler Thromb Vasc Biol 19 (1999) 1986-1991
20. Visser M., Bouter L.M., McQuillan G.M., Wener M.H., and Harris T.B. Elevated C-reactive protein levels in overweight and obese adults. JAMA 282 (1999) 2131-2135
21. Lin R., Liu J., Gan W., and Yang G. C-reactive protein-induced expression of CD40-CD40L and the effect of lovastatin and fenofibrate on it in human vascular endothelial cells. Biol Pharm Bull 27 (2004) 1537-1543
22. Pearson T.A., Mensah G.A., Alexander R.W., Anderson J.L., Cannon III R.O., Criqui M., et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107 (2003) 499-511
23. Azar R.R., Badaoui G., Sarkis A., Kassab R., Salame E., Klayme S., et al. Effects of tirofiban and statins on high-sensitivity C-reactive protein, interleukin-6, and soluble CD40 ligand following percutaneous coronary interventions in patients with stable coronary artery disease. Am J Cardiol 95 (2005) 236-240